Diabetes

Vitamin-based therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture (PMSF) encompassing Pyridoxamine (PM) and Sildenafil (SF)  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 18/January/2017, 12.27 pm
Vitamin-based therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture (PMSF) encompassing Pyridoxamine (PM) and Sildenafil (SF)  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 18/January/2017, 12.27 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

read more

Vitamin-based therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture (PMSF) encompassing Pyridoxamine (PM) and Sildenafil (SF) decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 18/January/2017, 11.54 am
Vitamin-based therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture (PMSF) encompassing Pyridoxamine (PM) and Sildenafil (SF) decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 18/January/2017, 11.54 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by neuronal cell adhesion molecule1.”…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: Melatonin, a hormone that regulates sleep and wakefulness, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 17/January/2018, 10.10 am
Molecular therapy for body weight control, energy homeostasis and TIIDM: Melatonin, a hormone that regulates sleep and wakefulness, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 17/January/2018, 10.10 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: Fluoxetine[Trade name: Prozac and Sarafem], an antidepressant,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 16/January/2018, 4.55 am
Molecular therapy for body weight control, energy homeostasis and TIIDM: Fluoxetine[Trade name: Prozac and Sarafem], an antidepressant,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 16/January/2018, 4.55 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

Vitamin-based combinatorial therapy for reversing TIIDM: A pharmaceutical mixture encompassing Vitamin-B12  and Omega-3-fatty acids (VB12O3FA)  augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 12/January/2017, 11.22 pm
Vitamin-based combinatorial therapy for reversing TIIDM: A pharmaceutical mixture encompassing Vitamin-B12  and Omega-3-fatty acids (VB12O3FA)  augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 12/January/2017, 11.22 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Combinatorial therapy for reversing TIIDM: A pharmaceutical mixture encompassing (TMZATX) Trimetazidine (TMZ) and Astaxanthin (ATX) augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 11/January/2017, 10.51 pm
Combinatorial therapy for reversing TIIDM: A pharmaceutical mixture encompassing (TMZATX) Trimetazidine (TMZ) and Astaxanthin (ATX) augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 11/January/2017, 10.51 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more
Start Typing